Isao Teshirogi, Shionogi CEO (Kiyoshi Ota/Bloomberg via Getty Images)
Shionogi backs F2G in developing rare-disease antifungal in Europe and Asia
Shionogi, an active player in the arid field of antimicrobials, has now set its eye on the adjacent sphere of antifungals.
The Japan-based pharma is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
